1. Home
  2. BPMC vs CPB Comparison

BPMC vs CPB Comparison

Compare BPMC & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPMC
  • CPB
  • Stock Information
  • Founded
  • BPMC 2008
  • CPB 1869
  • Country
  • BPMC United States
  • CPB United States
  • Employees
  • BPMC N/A
  • CPB N/A
  • Industry
  • BPMC Biotechnology: Pharmaceutical Preparations
  • CPB Packaged Foods
  • Sector
  • BPMC Health Care
  • CPB Consumer Staples
  • Exchange
  • BPMC Nasdaq
  • CPB Nasdaq
  • Market Cap
  • BPMC 8.3B
  • CPB 9.2B
  • IPO Year
  • BPMC 2015
  • CPB N/A
  • Fundamental
  • Price
  • BPMC N/A
  • CPB $32.66
  • Analyst Decision
  • BPMC Buy
  • CPB Hold
  • Analyst Count
  • BPMC 18
  • CPB 17
  • Target Price
  • BPMC $128.87
  • CPB $39.19
  • AVG Volume (30 Days)
  • BPMC 4.3M
  • CPB 6.0M
  • Earning Date
  • BPMC 07-31-2025
  • CPB 08-28-2025
  • Dividend Yield
  • BPMC N/A
  • CPB 4.78%
  • EPS Growth
  • BPMC N/A
  • CPB N/A
  • EPS
  • BPMC N/A
  • CPB 1.50
  • Revenue
  • BPMC $562,121,000.00
  • CPB $10,225,000,000.00
  • Revenue This Year
  • BPMC $44.46
  • CPB $7.68
  • Revenue Next Year
  • BPMC $32.78
  • CPB N/A
  • P/E Ratio
  • BPMC N/A
  • CPB $21.73
  • Revenue Growth
  • BPMC 99.19
  • CPB 8.65
  • 52 Week Low
  • BPMC $73.04
  • CPB $29.39
  • 52 Week High
  • BPMC $129.65
  • CPB $52.81
  • Technical
  • Relative Strength Index (RSI)
  • BPMC 3.63
  • CPB 55.80
  • Support Level
  • BPMC $129.20
  • CPB $30.70
  • Resistance Level
  • BPMC $129.65
  • CPB $31.53
  • Average True Range (ATR)
  • BPMC 0.18
  • CPB 0.90
  • MACD
  • BPMC -16.40
  • CPB 0.36
  • Stochastic Oscillator
  • BPMC 0.00
  • CPB 79.56

About BPMC Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

About CPB Campbell Soup Company

Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2024 (July year-end), snacks accounted for nearly half of its revenue, followed by soup (28%), other simple meals (17%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in March 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.

Share on Social Networks: